NewsRoom Articles - Page 753 of 1390

FridayJun 07, 2019 10:33 am

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) Signs Partnership Agreement, Expands into Nevada

PLUS recently entered into a definitive partnership agreement with TapRoot Holdings Inc. As PLUS expands beyond its home market of California, it wants to ensure that its product remains consistent TapRoot offers Nevada licenses and industry knowledge, enabling rapid deployment into new markets Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF), a manufacturer and marketer of cannabis food products, has expanded beyond its home market of California. The company has entered into a definitive partnership agreement with TapRoot Holdings Inc., which holds seven retail licenses in Nevada and has a deep understanding of the Nevada market (http://nnw.fm/Ti5I0). PLUS entered Nevada with…

FridayJun 07, 2019 10:03 am

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P) Develops Vertically Integrated Cannabis Portfolio, Forecasts Revenue Growth

Analysts predict that the global legal marijuana market will reach $146.4 billion in annual sales by 2025 Nabis Holdings is building assets across the cannabis spectrum in multiple states, with visions of international expansion, to capitalize on the trending market Thanks primarily to acquired assets and LOI-process holdings in Michigan, Nabis anticipates a significant revenue and EBITDA jump between 2019 and 2020 as cultivation facilities come online and recreational market sales begin The tremendous growth in a variety of cannabis-use industries capitalizing on the plant’s lifestyle-enhancing properties has opened a wide field of investment opportunity to Nabis Holdings (CSE: NAB)…

ThursdayJun 06, 2019 12:57 pm

World Crypto Conference Set to Take Center Stage During Vegas Blockchain Week in October

It may be that what happens in Vegas stays in Vegas, but word of the upcoming World Crypto Conference (WCC), to be held October 29-31, 2019, is already out. Hosted by event management company EVOLV, the Second Annual Blockchain and Cryptocurrency Technology conference will take over two levels of The Cosmopolitan of Las Vegas. The Cosmopolitan boasts 150,000 square feet of convention space, as well as a casino that stretches over 110,000 square feet. The event is expected to attract application developers; advisory, auditing and academic institutions; executives and enthusiasts; financial service providers; investment firms; and traders, as well as government policy…

ThursdayJun 06, 2019 12:29 pm

SinglePoint Inc. (SING) Expands Reach into Renewable Energy Market with Acquisition of Direct Solar

SinglePoint’s acquisition of Direct Solar is expected to increase the company’s revenues by $5 million in the first 12 months The solar panel market is projected to exceed $22 billion by 2025 Direct Solar’s model allows for quick, efficient expansion throughout the U.S. and globally Energy efficient, renewable energy technologies are quickly gaining a permanent spot in homes and commercial buildings across North America and around the world. SinglePoint Inc. (OTCQB: SING) CEO Greg Lambrecht said in a news release that SING’s recent asset acquisition of Direct Solar and affiliate AI Live Transfers catapults the technology and investment company into…

ThursdayJun 06, 2019 11:54 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers 475% More CBD to the Bloodstream

LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading volumes A DehydraTECH formulation achieved a 319 percent higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH delivery technology has demonstrated in animal lab tests that it can deliver cannabinoids to the bloodstream more quickly than conventional cannabinoid formulations (http://nnw.fm/fsKW4). At 15 minutes into the test, the DehydraTECH formulation achieved a…

ThursdayJun 06, 2019 11:28 am

City View Green Holdings Inc. (CSE: CVGR) Working to Be Premier Purveyor of Medicinal, Recreational Cannabis Products

City View Green Holdings’ emphasis is on creating a well-diversified cannabis business The company’s focus is premium edible offerings, distillates and water-soluble products The company leases a 40,000-square-foot facility in Ontario A vertically integrated cannabis company, City View Green Holdings Inc. (CSE: CVGR) focuses on seed to retail. The company’s application to Health Canada for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license is currently at the in-depth review stage of the licensing process. Based in Toronto, City View (formerly Icon Exploration Inc.) leases a 40,000-square-foot facility in Brantford, Ontario. Upon receipt of its cannabis act license, City…

ThursdayJun 06, 2019 10:55 am

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) to Acquire Soldaze Cannabis Snacks; Video Highlights California Production Hub’s Value

TransCanna Holdings has signed an LOI to acquire Soldaze cannabis-infused fruit snacks, one of its 15 planned premium cannabis brands TransCanna’s recently acquired 196,000-square-foot self-contained production and distribution facility in Modesto, California, was featured in a new video tour of the site The facility is being developed as a hub for statewide distribution to various company satellite facilities in premium markets The company has plans for developing a still-larger cultivation facility on the 5.5-acre Modesto site as it grows and obtains more funding TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) has signed a non-binding letter of intent, dated May 15,…

WednesdayJun 05, 2019 3:40 pm

CytoDyn Inc. (CYDY) Starts Presentation at 9th Annual LD Micro Invitational

CytoDyn (OTCQB: CYDY) is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The company plans to seek FDA approval for PRO 140 in combination therapy and…

WednesdayJun 05, 2019 3:40 pm

Eastside Distilling Inc. (NASDAQ: EAST) Starts Presentation at 9th Annual LD Micro Invitational

Eastside Distilling (NASDAQ: EAST) has been producing high-quality, award-winning craft spirits since 2008. The company is distinguished by its highly decorated product lineup that includes Burnside Bourbon, West End American Whiskey, Goose Hollow Reserve, Below Deck Rums, Portland Potato Vodka, Hue-Hue Coffee Rum and a distinctive line of fruit infused spirits. Eastside Distilling is majority owner of Big Bottom and the Redneck Riviera Whiskey Co. All Eastside, Big Bottom and Redneck Riviera spirits are crafted from natural ingredients for quality and taste. Eastside’s Mother Lode Bottling subsidiary is one of the Northwest’s leading independent spirit bottlers and ready-to-drink canners. For…

WednesdayJun 05, 2019 3:00 pm

Wize Pharma Inc. (WIZP) Starts Presentation at 9th Annual LD Micro Invitational

Wize Pharma (OTCQB: WIZP) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's syndrome (Sjögren's). Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a phase IV study for LO2A for DES in patients with Sjögren's. For more information, visit…

Financial news and publishing for public and private companies

Contact us: 512.354.7000